부산대학교 도서관

Objective: To determine the parameters that can predict upgrade with muitiparametric magnetic resonance imaging (mpMRI) findings before radical prostatectomy (RP) in prostate cancer. The development of mpMRI increases the prediction rate of upgrades. Materials and Methods: The study included 69 patients who were diagnosed with prostate cancer (PCa) between January 2017-December 2020 and subsequently underwent RR Patients were divided into two groups by comparing prostate biopsies and RP specimens as patients with upgrade (group 1) and patients without upgrade (group 2). Of the 69 patients, 26 were in group 1 and 43 in group 2. The images were evaluated by a single radiologist experienced in mpMRI using the Prostate Imaging Reporting and Data System v2.1 scoring system. Biopsy and RP pathology specimens were evaluated by an experienced neuropathologist. Results: The median prostate-specific antigen (PSA) levels were higher in patients with upgraded pathology [8.60 (5.90-14.00) ng/dL vs. 7.70 (5.20-10.00) ng/dL, respectively; p=0.040]. The prostate volume [31.88 (23.40-51.48) vs. 48.06 (23.40-87.35); p=0.009] and PSA density [3.72 (2.17-5.62) vs. 5.75 (3.35-9.6), respectively; p=0.007] were lower in patients with upgraded pathology. The tumor percentage on mpMRI was not different between the groups [3.70 (1.80-16.20 vs. 2.50 (1.10-6.60); p=0.076]. The histopathological tumor percentage was significantly higher in patients with upgraded histology (p=0.006). Conclusions: Although the percentage of tumors on muitiparametric mpMRI is an inadequate pattern to predict upgrade in PCa patients, prospective studies designed to evaluate its potential will be of great interest. Keywords: Muitiparametric magnetic resonance imaging, prostate cancer, radical prostatectomy, tumor percentage, upgrade
Introduction Prostate cancer (PCa) is the most common malignancy and the second most common cause of cancer-related deaths in males (1). Serum prostate-specific antigen (PSA) evaluation has shown that its [...]